No Prescription |
 |
 | ||
|
Gliclazide Glyade |
|
| ||
No Prescription » Prescription Drugs 8 » Gliclazide Glyade Oral antidiabetic agent.Gliclazide is used to treat Non Insulin Dependent Diabetes Mellitus.Dosage Initially 40 mg daily may increase to max 320 mg daily. Doses >160 mg should be given in 2 divided doses. Buy Gliclazide Glyade and other Prescription Drugs 8 products online at Medstore. 5301
About Gliclazide Glyade: Product Type: Prescription Drugs 8 Gliclazide ( Glyade Generic Diamicron ) Gliclazide (Glyade Generic Diamicron) Glyade Generic Diamicron 80mg 500 Tablets Glyade Generic Diamicron Gliclazide
View more Prescription Drugs 8 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
